for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CytomX Therapeutics Inc

CTMX.OQ

Latest Trade

8.99USD

Change

-0.20(-2.18%)

Volume

387,836

Today's Range

8.77

 - 

9.34

52 Week Range

8.07

 - 

19.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.19
Open
9.15
Volume
387,836
3M AVG Volume
6.25
Today's High
9.34
Today's Low
8.77
52 Week High
19.67
52 Week Low
8.07
Shares Out (MIL)
45.41
Market Cap (MIL)
408.23
Forward P/E
-4.41
Dividend (Yield %)
--

Latest Developments

More

CytomX Therapeutics Announces Qtrly Loss Per Share $0.64

CytomX Therapeutics Reports Second Target Selection And Program Initiation With AbbVie

CytomX Therapeutics Says On May 22, Board Designated Dr. Sean Mccarthy, Co's Chairman & CEO, To Assume Responsibilities Of Principal Financial Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Industry

Biotechnology & Drugs

Contact Info

151 Oyster Point Blvd Ste 400

+1.650.5153185

http://cytomx.com/

Executive Leadership

Sean A. McCarthy

Chairman of the Board, President, Chief Executive Officer

Lloyd A. Rowland

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Nick Galli

Senior Vice President, Chief Business Officer

W. Michael Kavanaugh

Chief Scientific Officer and Head - Research and Non-Clinical Development

Matthew P. Young

Lead Independent Director

Key Stats

1.90 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.630

2017

-1.160

2018

-2.030

2019(E)

-2.039
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.53
Price To Book (MRQ)
4.02
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-31.84
Return on Equity (TTM)
-25.25

Latest News

BRIEF-CytomX Therapeutics Q1 Revenue $14.2 Mln Vs I/B/E/S View $16.4 Mln

* CYTOMX THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytomx Therapeutics Provides Operational Update

* CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

BRIEF-Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8

* PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING Source text (http://bit.ly/2BGceJ2) Further company coverage:

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

BRIEF-CytomX reports Q3 loss per share $‍0.28​

* CytomX announces third quarter 2017 financial results and operational progress

BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors

* CytomX Therapeutics Inc appoints Charles S. Fuchs, M.D., MPH to board of directors Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics Q2 loss per share $ 0.69​

* Cytomx announces second quarter 2017 financial results and mid-year update webcast conference call

BRIEF-Canaan IX LP dissolves passive stake in Cytomx Therapeutics as of June 7 - SEC filing

* Canaan IX LP dissolves passive stake in Cytomx Therapeutics Inc as of June 7 - SEC filing

BRIEF-BVF Partners LP reports 5.5 pct passive stake in CytomX Therapeutics as of June 19 - SEC Filing

* BVF Partners LP reports 5.5 percent passive stake in CytomX Therapeutics Inc as of June 19 - SEC Filing Source text: [http://bit.ly/2trugL5] Further company coverage:

BRIEF-CytomX achieves development milestone in collaboration with AbbVie

* CytomX achieves development milestone in strategic oncology collaboration with AbbVie for CD71-targeting probody drug conjugate

BRIEF-Cytomx announces management team changes

* Bob Goeltz, chief financial officer, has decided to leave company to pursue new opportunities

BRIEF-CytomX Therapeutics qtrly loss per share $ 0.23

* Q1 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S

BRIEF-Cytomx Therapeutics announces proposed resale of up to 10.9 mln shares by selling stockholders

* Cytomx Therapeutics Inc - files for proposed resale or other disposition of up to 10.9 million shares of co by the selling stockholders - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Cytomx announces full-year 2016 financial results

* Cytomx announces full-year 2016 financial results Source text for Eikon: Further company coverage:

BRIEF-Cytomx announces the first patient treated in phase 1/2 proclaim-072 trial

* Cytomx announces the first patient treated in phase 1/2 proclaim-072 trial Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics files for mixed shelf of upto $250 mln - SEC filing

* Cytomx Therapeutics Inc - files for mixed shelf of upto $250 million - SEC filing Source text: (http://bit.ly/2fmn5Jx) Further company coverage:

BRIEF-Cytomx therapeutics announces Q3 2016 results; provides pipeline update

* Qtrly loss per share $0.40; co expects "its existing capital resources will be sufficient to fund operations through 2018"

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up